Last reviewed · How we verify

Seretide® Accuhaler® 250/50 µg/actuation — Competitive Intelligence Brief

Seretide® Accuhaler® 250/50 µg/actuation (Seretide® Accuhaler® 250/50 µg/actuation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS). Area: Respiratory / Pulmonology.

phase 3 Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; Glucocorticoid receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Seretide® Accuhaler® 250/50 µg/actuation (Seretide® Accuhaler® 250/50 µg/actuation) — Chiesi Farmaceutici S.p.A.. Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Seretide® Accuhaler® 250/50 µg/actuation TARGET Seretide® Accuhaler® 250/50 µg/actuation Chiesi Farmaceutici S.p.A. phase 3 Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; Glucocorticoid receptor
Salmeterol/Fluticasone Capsair® Salmeterol/Fluticasone Capsair® Neutec Ar-Ge San ve Tic A.Ş marketed Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/fluticasone Diskus Salmeterol/fluticasone Diskus AstraZeneca marketed Long-acting beta-2 agonist/inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor
Seretide 500 Accuhaler Seretide 500 Accuhaler University of Southampton marketed Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/ fluticasone propionate Salmeterol/ fluticasone propionate GlaxoSmithKline marketed Long-acting beta-2 agonist / inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor
Extra fine Formoterol/Beclomethasone Extra fine Formoterol/Beclomethasone National Institute of Respiratory Diseases, Mexico marketed Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) Beta-2 adrenergic receptor; glucocorticoid receptor
Seretide Accuhaler® 500/50 µg/actuation Seretide Accuhaler® 500/50 µg/actuation Chiesi Farmaceutici S.p.A. phase 3 Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) Beta-2 adrenergic receptor; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS) class)

  1. Chiesi Farmaceutici S.p.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Seretide® Accuhaler® 250/50 µg/actuation — Competitive Intelligence Brief. https://druglandscape.com/ci/seretide-accuhaler-250-50-g-actuation. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: